Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$353.6MCash, Jun 2026
25moCash Runway (est.)
+9%Share Count, 1 Year
Follow CGEM by emailGet an email when CGEM pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CGEM, unsubscribe in one click. Privacy
💊 Upcoming FDA Decisions
PDUFA Date
Drug
Indication
Type
PoA
2027-02-27
—
NDA
66%
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area and cash runway. Not investment advice. See the full PDUFA calendar →
📣 What CGEM Says Is Next
by year-end 2026 · “Completion of the NDA submission is expected by year-end 2026.”
Company press release, Oct 2, 2026 · SEC filing
Q4 2026 · “Additional multi-dose regimen data from the study are expected to be shared in Q4 2026. o Cullinan plans to initiate a global Phase 1/2 basket study in early 2027 in patients with autoimmune cytopenias, including immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA).”
Company press release, Aug 6, 2026 · SEC filing
early 2027 · “The Company also plans to begin Phase 2 expansion in early 2027.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
CGEM reported $353.6M in cash and short-term investments (as of Jun 30, 2026) and used about $42.5M/quarter in operations, an estimated runway of 25 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:33 · Moderate
Cash runway 25 months
ATM program on file since Apr 2026 +15
Shelf registration (S-3ASR, Apr 2026) +10
FDA decision in 147 days +8
Recent financing filings on SEC EDGAR:
Apr 28, 2026 · Shelf registration with ATM program, up to $200M · S-3ASR
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CGEM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.